Skip to main content
Premium Trial:

Request an Annual Quote

Detroit R&D Awarded $1M Phase II SBIR Grant

NEW YORK (GenomeWeb News) – Detroit R&D today announced it has been granted a two-year $1 million Small Business Innovation Research Phase II grant to continue research into protein glycosylation.

The grant from the National Cancer Institute will be used by the company to continue work carried out with a Phase I SBIR grant in 2012 for $300,000, it said. In the Phase I study, Detroit R&D developed glycosylation site-specific antibodies for oncogene proteins and cancer-suppressor proteins, as well as methods for screening anti-cancer drugs. The company developed a microarray-based method for screening glycosylated protein biomarkers in prostate cancer.

With the new funding, the company plans to produce approximately 40 site-specific antibodies for glycosylated receptors and signal transduction pathway proteins. Detroit R&D also plans to elucidate the functions of protein glycosylation in cancer, it said.

The research is anticipated to lead to the development of diagnostics and therapeutics directed at breast, prostate, and pancreatic cancers.

The Phase II study lasts until September 2015.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.